Victoria Sheridan, Craig W. Duffy, Jake Dunning, Lance Turtle, Julian A. Hiscox, Krishanthi S. Subramaniam, on behalf of the ISARIC4C Investigators
A 2-dose regimen of the vaccine modified vaccinia Ankara-Bavarian Nordic (MVA-BN) can generate neutralizing antibodies for monkeypox virus clades Ib and IIb. We observed higher response to clade IIb; that result provides evidence that MVA-BN vaccination can induce cross-neutralizing antibodies for monkeypox virus clade Ib as well as for clade IIb.